ストックスクリーナーアプリを入手
0.9146
0.95%
-0.0088
前日終値:
$0.9234
開ける：
$0.92
24時間の取引高:
230.37K
Relative Volume:
0.47
時価総額：
$14.19M
収益：
-
当期純損益:
$-12.16M
株価収益率:
-0.859
EPS:
-1.0647
ネットキャッシュフロー:
$-9.68M
1週間 パフォーマンス:
-11.20%
1か月 パフォーマンス:
-12.90%
6か月 パフォーマンス:
-49.19%
1年 パフォーマンス:
-14.52%
1日の値動き範囲:
$0.88
$0.9458
1週間の範囲:
$0.88
$1.07
52週間の値動き範囲:
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
名前
Hoth Therapeutics Inc
セクター
電話
(646)756-2997
住所
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ALNY, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.9146 | 14.19M | 0 | -12.16M | -9.68M | -1.0647 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.59 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-10-15 | 開始されました | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc (HOTH) 最新ニュース
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA - MSN
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Fed Meeting: Will Hoth Therapeutics Inc announce a stock splitMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Aug EndMonth: How much upside does Hoth Therapeutics Inc have2026 Setups & Advanced Technical Signal Analysis - baoquankhu1.vn
Hoth Therapeutics reports preclinical data on obesity treatment - Investing.com Nigeria
Hoth Therapeutics reports preclinical data on obesity treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model - PR Newswire
ETF Watch: Will Hoth Therapeutics Inc. benefit from rising consumer demandWeekly Profit Summary & Stock Portfolio Risk Control - baoquankhu1.vn
Market Outlook: Is Hoth Therapeutics Inc benefiting from innovation trendsPortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Published on: 2026-03-07 13:26:02 - baoquankhu1.vn
Jobs Data: Will Hoth Therapeutics Inc announce a stock splitPortfolio Performance Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Breakout Zone: Whats the fair value of Hoth Therapeutics Inc stockEarnings Recap Report & Capital Protection Trade Alerts - baoquankhu1.vn
Hoth Therapeutics (NASDAQ: HOTH) Is Heating Up – New Site Added - Bitget
Hoth Therapeutics Integrates OpenAI API to Advance HT-KIT Oncology Program for Mast Cell-Derived Cancers - geneonline.com
Analyst Maintains Buy Rating for Hoth Therapeutics (HOTH) | HOTH Stock News - GuruFocus
Hoth Therapeutics Deploys OpenAI API to Support Development of HT-KIT - Contract Pharma
Hoth Therapeutics deploys Openai API to advance development of orphan HT-KIT oncology program - marketscreener.com
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program - PR Newswire
EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers - Benzinga
HOTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HOTH.O| Stock Price & Latest News - Reuters
Aug Selloffs: Is Hoth Therapeutics Inc stock trending bullishPortfolio Risk Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
HOTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hoth Therapeutics adds clinical site for skin toxicity trial - Investing.com India
Hoth Therapeutics Expands Clinical Trial for Cancer Skin Toxicity Treatment - National Today
Hoth Therapeutics adds clinical site for skin toxicity trial By Investing.com - Investing.com Australia
Hoth Therapeutics accelerates HT-001 trial enrollment with new clinical site as patient demand increases - marketscreener.com
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES - PR Newswire
Performance Recap: Will Lufax Holding Ltd Depositary Receipt benefit from geopolitical trendsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
Aug Reactions: Whats the outlook for Hoth Therapeutics Incs sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Cancer rash drug HT-001 draws so many patients Hoth adds Miami site - Stock Titan
Will Hoth Therapeutics Inc. announce a stock splitCPI Data & Technical Pattern Recognition Alerts - mfd.ru
HOTH Should I Buy - Intellectia AI
Is Hoth Therapeutics Inc. stock trending bullishJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - mfd.ru
Hoth Therapeutics receives U.S. notice of allowance for novel exon-skipping therapy targeting allergic diseases - marketscreener.com
Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases - TradingView
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases - PR Newswire
Hoth’s obesity treatment outperforms semaglutide in preclinical study - Investing.com Australia
Why Hoth Therapeutics Inc. stock is a must watch in 2025Trade Volume Summary & Pattern Based Trade Signal System - mfd.ru
Hoth’s obesity treatment outperforms semaglutide in preclinical study By Investing.com - Investing.com Nigeria
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics - Intellectia AI
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Asianet Newsable
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits
Hoth Therapeutics announces groundbreaking positive results: HT-VA GDNF surpasses Semaglutide in weight loss - marketscreener.com
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment - Intellectia AI
Hoth Therapeutics rises as early obesity‑drug data in mice shows promise - TradingView
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model - PR Newswire
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Benzinga
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - Eastern Progress
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets - marketscreener.com
Hoth Therapeutics Inc (HOTH) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
大文字化:
|
ボリューム (24 時間):